Back to results

EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke (DISTAL)

Primary Purpose

Acute Ischemic Stroke

Status

Recruiting

Phase

Not Applicable

Locations

International

Study Type

Interventional

Intervention

Endovascular Therapy

About this trial

This is an interventional treatment trial for Acute Ischemic Stroke focused on measuring Stroke, Medium Vessel Occlusion, Endovascular Therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Acute ischemic stroke
Treatment (arterial puncture) can be initiated 2.1. Within 6 hours of last seen well (LSW) OR 2.2. Within 6 to 24 hours of LSW AND
CT Criteria: Evidence of a hypoperfusion-hypodensity mismatch (Absence of hypodensity on the noncontrast CT within ≥ 90% of the area of the hypoperfused lesion on perfusion CT)
MRI Criteria: Evidence of a diffusion-hyperintensity mismatch (Absence of hyperintensity on fluid-attenuated inversion recovery (FLAIR) imaging within ≥ 90% of the area of the diffusion weighted imaging(DWI) lesion)
Isolated medium vessel occlusion (i.e. an occlusion of the co-/non-dominant M2, the M3/M4 segment of theMCA, the A1/A2/A3 segment of the ACA or the P1/P2 segment of the PCA) confirmed by CT or MRIAngiography
National Institute of Health Stroke Scale (NIHSS) Score of ≥ 4 points or symptoms deemed clearly disabling by treating physician (i.e. aphasia, hemianopia, etc.)
Informed Consent as documented by signature or fulfilling the criteria for emergency consent/ deferral consent
Agreement of treating physician to perform endovascular procedure

Exclusion Criteria:

Acute intracranial haemorrhage
Patient bedridden or presenting from a nursing home
In-Hospital Stroke
Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals or their alloys
Foreseeable difficulties in follow-up due to geographic reasons (e.g. patients living abroad)
Pregnancy or lactating women. A negative pregnancy test before randomisation is required for all women with child-bearing potential.
Known history of arterial tortuosity, pre-existing stent, other arterial disease and/or known disease at the arterial access site that would prevent the device from reaching the target vessel and/or preclude safe recovery after EVT
Severe comorbidities, which will likely prevent improvement or follow-up
Radiological confirmed evidence of mass effect or intracranial tumour (except small meningioma)
Radiological confirmed evidence of cerebral vasculitis
Evidence of vessel recanalization prior to randomisation
Participation in another interventional trial

Sites / Locations

Universitair Ziekenhuis BrusselRecruiting
Hôpital Civil Marie Curie CharleroiRecruiting
UZ Universiteit GentRecruiting
AZ GroeningeRecruiting
Universitair Ziekenhuis LeuvenRecruiting
Clinique CHC MontLégiaRecruiting
Helsinki University HospitalRecruiting
Uniklinik RHTW Aachen
Charité-Universitätsmedizin BerlinRecruiting
Universitätsklinikum Knappschaftskrankenhaus BochumRecruiting
Uniklinikum DresdenRecruiting
University Hospital Hamburg EppendorfRecruiting
LMU Klinikum MünchenRecruiting
Universitätsklinikum der Technischen Universität MünchenRecruiting
Klinikum NürnbergRecruiting
Klinikum VEST GmbHRecruiting
Klinikum der Landeshauptstadt Stuttgart gKAöRRecruiting
Hospital Clinico BarcelonaRecruiting
Hospital Vall d'HebronRecruiting
University Hospital Germans Trias i PujolRecruiting
Hospital Clinico Universitario de ValladolidRecruiting
Kantonsspital Aarau, Department of Interventional and Diagnostical NeuroradiologyRecruiting
Department of Interventional and Diagnostical Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital BaselRecruiting
Department of Neurology, University Hospital BaselRecruiting
Inselspital Bern, University Clinic for NeuroradiologyRecruiting
Geneva University Hospitals, Interventional Neuroradiology UnitRecruiting
Centre hospitalier universitaire vaudois, CHUVRecruiting
Neurocentro (EOC) della Svizzera Italiana Stroke Center, Servizio di Neurologia, Ospedale CivicoRecruiting
Kantonsspital LuzernRecruiting
Kantonsspital St GallenRecruiting
University Hospital Zurich, Departement of NeuroradiologyRecruiting
Barts NHS Health Trust
University Hospitals of North Midlands NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention group: EVT + BMT

Control group: BMT

Arm Description

Patients randomized to the EVT arm will undergo endovascular therapy (EVT) in addition to best medical treatment (BMT). All decisions regarding EVT device and EVT technique will be made by the treating physician.

Patients randomized to the control arm will NOT undergo EVT but will get best medical treatment (BMT) including intravenous thrombolysis (IVT) or antiplatelet therapy if indicated under current international guidelines and according to routine clinical practice.

Outcomes

Primary Outcome Measures

Degree of dependency and disability in everyday life (measured with the mRS)

The primary outcome is the degree of dependency and disability in everyday life (measured with the mRS) at 90 days. The mRS is the standard tool to assess neurological outcome in trials with acute severe brain disease. The scale runs from 0-6, running from perfect health without symptoms (= 0) to death (= 6).

Secondary Outcome Measures

Change in National Institutes of Health Stroke Scale (NIHSS)

The scale is made up of 11 different elements that evaluate specific ability. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke patient is.

Assessment of Cognitive function using the validated Montreal cognitive assessment (MoCA)

MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.

Change in Quality of life as assessed by the EuroQol-5D

The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. the descriptive system produces a 5-digit health status profile that represents that person's level of reported problems on the five EQ-5D health dimensions

Degree of dependency and disability in everyday life (measured with the mRS)

Degree of dependency and disability in everyday life (measured with the mRS). The scale runs from 0-6, running from perfect health without symptoms (= 0) to death (= 6).

Patient residential status

Patient residential status will be obtained through a telephone call to the patient or if not available his next of kin/caregiver one year (± 30 days) after randomisation

Change in percentage of penumbral tissue saved (Imaging Data Evaluation)

Percentage of penumbral tissue saved (Imaging Data Evaluation): It is defined as the proportion of tissue at risk (defined as the mismatch volume derived from with RAPID Compute tomography perfusion (CTP) (IschemaView Inc.) at baseline that did not progress to infarction at 24h (derived from Magnet Resonance Imaging (MRI) (FLAIR and Diffusion Weighted Imaging (DWI)) or NCCT imaging.

Radiologic occurrence of intracranial haemorrhages

Radiologic occurrence of intracranial haemorrhages graded according to the modified Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) definition

Full Information

NCT ID

NCT05029414

First Posted

August 26, 2021

Last Updated

June 26, 2023

Sponsor

University Hospital, Basel, Switzerland

Collaborators

Swiss National Fund for Scientific Research, Stryker Neurovascular, Penumbra Inc., Medtronic, Phenox GmbH, Rapid Medical, Gottfried und Julia Bangerter-Rhyner-Stiftung

1. Study Identification

Unique Protocol Identification Number

NCT05029414

Brief Title

EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

Acronym

DISTAL

Official Title

EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke - a prAgmatic, International, Multicentre, Randomized triaL (DISTAL)

Study Type

Interventional

2. Study Status

Record Verification Date

June 2023

Overall Recruitment Status

Recruiting

Study Start Date

December 9, 2021 (Actual)

Primary Completion Date

December 2024 (Anticipated)

Study Completion Date

December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

University Hospital, Basel, Switzerland

Collaborators

Swiss National Fund for Scientific Research, Stryker Neurovascular, Penumbra Inc., Medtronic, Phenox GmbH, Rapid Medical, Gottfried und Julia Bangerter-Rhyner-Stiftung

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

5. Study Description

Brief Summary

Acute ischemic stroke (AIS) is one of the main causes of disability and loss of quality adjusted life years. This study is to analyze whether endovascular therapy (EVT) in addition to best medical treatment (BMT) reduces the degree of disability and dependency in daily activities after a Medium Vessel Occlusion (MeVO) stroke compared to BMT alone.

Detailed Description

Acute ischemic stroke (AIS) is one of the main causes of death and disability and thereby the third leading cause of loss of quality adjusted life years. For patients with an AIS due to an occlusion of the large vessels of the anterior circulation, endovascular therapy (EVT) has become a treatment standard. 20-40% of all AIS patients have occlusions of smaller vessels and present with a more distal isolated Medium Vessel Occlusion (MeVO). The primary objective of this randomized trial is to determine whether patients experiencing an AIS due to an isolated medium vessel occlusion have superior functional outcome (measured with the Modified Rankin Scale "mRS" at 90 days) when treated with EVT plus best medical treatment (BMT) compared to patients treated with BMT alone. In this trial, all commercially available, CE-certified revascularisation devices (i.e. stent-retriever, aspiration catheters and balloon guide catheters) can be used for EVT. All established techniques for the endovascular treatment of AIS patients are permitted and all decisions regarding treatment technique and choice of devices and/or medications are made solely by the treating physician.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Acute Ischemic Stroke

Keywords

Stroke, Medium Vessel Occlusion, Endovascular Therapy

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Model Description

Pragmatic, parallel group, randomized, open label, superiority trial with blinded endpoint assessment

Masking

Outcomes Assessor

Masking Description

A treatment-blinded person will assess the primary outcome dependency and disability in everyday life (measured with the modified Rankin Scale (mRS)) at 90 days. All interviewers will be certified for the conductance of mRS. interviews.

Allocation

Randomized

Enrollment

526 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

Intervention group: EVT + BMT

Arm Type

Experimental

Arm Description

Arm Title

Control group: BMT

Arm Type

No Intervention

Arm Description

Intervention Type

Procedure

Intervention Name(s)

Endovascular Therapy

Intervention Description

Endovascular treatment of stroke is the non-surgical treatment for the sudden loss of brain function due to blood clots. The blood clot is removed from the blood via devices (i.e. stent-retriever, aspiration catheters and balloon guide) to achieve revascularization.

Primary Outcome Measure Information:

Title

Degree of dependency and disability in everyday life (measured with the mRS)

Description

Time Frame

at 90 days (± 14 days) after randomisation

Secondary Outcome Measure Information:

Title

Change in National Institutes of Health Stroke Scale (NIHSS)

Description

Time Frame

24 hours post-randomization (+/- 6 hours)

Title

Assessment of Cognitive function using the validated Montreal cognitive assessment (MoCA)

Description

MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.

Time Frame

at 90 days (± 14 days) after randomisation

Title

Change in Quality of life as assessed by the EuroQol-5D

Description

Time Frame

at 90 ± 14 days and at 1 year after randomisation

Title

Degree of dependency and disability in everyday life (measured with the mRS)

Description

Degree of dependency and disability in everyday life (measured with the mRS). The scale runs from 0-6, running from perfect health without symptoms (= 0) to death (= 6).

Time Frame

at one year (± 30 days) after randomisation

Title

Patient residential status

Description

Patient residential status will be obtained through a telephone call to the patient or if not available his next of kin/caregiver one year (± 30 days) after randomisation

Time Frame

at one year (± 30 days) after randomisation

Title

Change in percentage of penumbral tissue saved (Imaging Data Evaluation)

Description

Time Frame

at baseline and post-interventional at 24 hours (± 6 hours) post-randomisation

Title

Radiologic occurrence of intracranial haemorrhages

Description

Radiologic occurrence of intracranial haemorrhages graded according to the modified Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) definition

Time Frame

within 24 hours (± 6 hours) post randomisation

Other Pre-specified Outcome Measures:

Title

Change in All-cause mortality (Safety Outcome)

Description

Change in All-cause mortality

Time Frame

at days 7-10 or discharge if earlier, 90 day ± 14 days; and one year ± 30 days after randomisation.

Title

Change in Serious Adverse Events (SAEs)

Description

Change in Serious Adverse Events (SAEs)

Time Frame

at 24 h ± 6h, days 7-10 or discharge if earlier and at 90 ± 14 days after randomisation

Title

Change in symptomatic intracranial haemorrhage

Description

Change in symptomatic intracranial haemorrhage by radiologic categorization on the basis of the pre-randomisation imaging at day 0 (Non contrast computed tomography (NCCT)/Magnet Resonance Imaging (MRI), Computed tomography angiography (CTA)/Magnetic Resonance Angiography (MRA), Diffusion Weighted Imaging (DWI)/Perfusion Weighted Imaging (PWI) MRI, Compute tomography (CT) perfusion) and the post-interventional imaging at 24 ± 6 hours.

Time Frame

at 24 ± 6 hours post randomisation

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Acute ischemic stroke Treatment (arterial puncture) can be initiated 2.1. Within 6 hours of last seen well (LSW) OR 2.2. Within 6 to 24 hours of LSW AND CT Criteria: Evidence of a hypoperfusion-hypodensity mismatch (Absence of hypodensity on the noncontrast CT within ≥ 90% of the area of the hypoperfused lesion on perfusion CT) MRI Criteria: Evidence of a diffusion-hyperintensity mismatch (Absence of hyperintensity on fluid-attenuated inversion recovery (FLAIR) imaging within ≥ 90% of the area of the diffusion weighted imaging(DWI) lesion) Isolated medium vessel occlusion (i.e. an occlusion of the co-/non-dominant M2, the M3/M4 segment of theMCA, the A1/A2/A3 segment of the ACA or the P1/P2/P3 segment of the PCA) confirmed by CT or MRIAngiography National Institute of Health Stroke Scale (NIHSS) Score of ≥ 4 points or symptoms deemed clearly disabling by treating physician (i.e. aphasia, hemianopia, etc.) Informed Consent as documented by signature or fulfilling the criteria for emergency consent/ deferral consent Agreement of treating physician to perform endovascular procedure Exclusion Criteria: Acute intracranial haemorrhage Patient bedridden or presenting from a nursing home In-Hospital Stroke Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals or their alloys Foreseeable difficulties in follow-up due to geographic reasons (e.g. patients living abroad) Pregnancy or lactating women. A negative pregnancy test before randomisation is required for all women with child-bearing potential. Known history of arterial tortuosity, pre-existing stent, other arterial disease and/or known disease at the arterial access site that would prevent the device from reaching the target vessel and/or preclude safe recovery after EVT Severe comorbidities, which will likely prevent improvement or follow-up Radiological confirmed evidence of mass effect or intracranial tumour (except small meningioma) Radiological confirmed evidence of cerebral vasculitis Evidence of vessel recanalization prior to randomisation Participation in another interventional trial

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Marios-Nikos Psychogios, Prof.Dr.

Phone

+41 61 328 59 36

distal@usb.ch

First Name & Middle Initial & Last Name or Official Title & Degree

Alex Brehm, PhD

Phone

+41 61 328 79 48

alex.brehm@usb.ch

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Marios-Nikos Psychogios, Prof.Dr.

Organizational Affiliation

Department of Interventional and Diagnostical Neuroradiology, University Hospital Basel

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Urs Fischer, Prof.Dr.

Organizational Affiliation

Neurology, Inselspital, Bern University Hospital

Official's Role

Principal Investigator

Facility Information:

Facility Name

Universitair Ziekenhuis Brussel

City

Brussel

Country

Belgium

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Petra Dierickx

Petra.Dierickx@uzbrussel.be

First Name & Middle Initial & Last Name & Degree

Frans Van den Bergh, Dr

Facility Name

Hôpital Civil Marie Curie Charleroi

City

Charleroi

Country

Belgium

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Anne Dusart, Dr

anne.dusart@chu-charleroi.be

First Name & Middle Initial & Last Name & Degree

Flavio Bellante, Dr

Facility Name

UZ Universiteit Gent

City

Gent

Country

Belgium

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Lynn Huyck

Lynn.Huyck@uzgent.be

First Name & Middle Initial & Last Name & Degree

Luc Defreyne, Prof

Facility Name

AZ Groeninge

City

Groeninge

Country

Belgium

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Anne-Sophie Desloovere

ANNE-SOPHIE.DESLOOVERE@azgroeninge.be

First Name & Middle Initial & Last Name & Degree

Olivier Francois, Dr

Facility Name

Universitair Ziekenhuis Leuven

City

Leuven

Country

Belgium

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Annemie Devroye

annemie.devroye@uzleuven.be

First Name & Middle Initial & Last Name & Degree

Robin Lemmens, Prof Dr

Facility Name

Clinique CHC MontLégia

City

Liege

Country

Belgium

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Karima Bouaassam

Karima.BOUAASSAM@CHC.BE

First Name & Middle Initial & Last Name & Degree

Philippe Desfontaines

Facility Name

Helsinki University Hospital

City

Helsinki

Country

Finland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Daniel Strbian, Prof

Daniel.Strbian@hus.fi

First Name & Middle Initial & Last Name & Degree

Daniel Strbian, Prof

Facility Name

Uniklinik RHTW Aachen

City

Aachen

Country

Germany

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Andrea Stockero

astockero@ukaachen.de

First Name & Middle Initial & Last Name & Degree

Martin Wiesmann, Prof Dr

Facility Name

Charité-Universitätsmedizin Berlin

City

Berlin

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Christian H Nolte, Professor

Phone

030 450 560676

christian.nolte@charite.de

First Name & Middle Initial & Last Name & Degree

Christian H Nolte, Prof. Dr.

First Name & Middle Initial & Last Name & Degree

Justus Kleine, Dr.

Facility Name

Universitätsklinikum Knappschaftskrankenhaus Bochum

City

Bochum

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Sebastian Fischer

Sebastian.Fischer@kk-bochum.de

First Name & Middle Initial & Last Name & Degree

Sebastian Fischer

Facility Name

Uniklinikum Dresden

City

Dresden

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Kathrin Haase

Kathrin.Haase2@ukdd.de

First Name & Middle Initial & Last Name & Degree

Daniel Kaiser, Dr

First Name & Middle Initial & Last Name & Degree

Volker Pütz, Dr

Facility Name

University Hospital Hamburg Eppendorf

City

Hamburg

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Götz Thomalla, Prof. Dr.

First Name & Middle Initial & Last Name & Degree

Götz Thomalla, Prof Dr

First Name & Middle Initial & Last Name & Degree

Jens Fiehler, Prof Dr

Facility Name

LMU Klinikum München

City

München

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Konstantinos Dimitriadis, Dr

Konstantin.Dimitriadis@med.uni-muenchen.de

First Name & Middle Initial & Last Name & Degree

Martin Dichgans, Prof Dr

Facility Name

Universitätsklinikum der Technischen Universität München

City

München

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Sandra Baudrexl

sandra.baudrexl@tum.de

First Name & Middle Initial & Last Name & Degree

Jan Kirschke, Prof Dr

Facility Name

Klinikum Nürnberg

City

Nürnberg

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Sabine Kohler

Sabine.Kohler@klinikum-nuernberg.de

First Name & Middle Initial & Last Name & Degree

Markus Holtmannspötter, Dr

First Name & Middle Initial & Last Name & Degree

Jan Liman, Prof Dr

Facility Name

Klinikum VEST GmbH

City

Recklinghausen

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

R Hilker-Roggendorf, Prof

First Name & Middle Initial & Last Name & Degree

R Hilker-Roggendorf, Prof

Facility Name

Klinikum der Landeshauptstadt Stuttgart gKAöR

City

Stuttgart

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Victoria Hellstern, Dr

v.hellstern@klinikum-stuttgart.de

First Name & Middle Initial & Last Name & Degree

Victoria Hellstern, Dr

Facility Name

Hospital Clinico Barcelona

City

Barcelona

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Martha Vargas

mvargas@clinic.cat

First Name & Middle Initial & Last Name & Degree

Sergio Amaro

Facility Name

Hospital Vall d'Hebron

City

Barcelona

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Marc J Ribo, PhD

First Name & Middle Initial & Last Name & Degree

Marc J Ribo, PhD

Facility Name

University Hospital Germans Trias i Pujol

City

Barcelona

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Martí Boix

bdnmarti@gmail.com

First Name & Middle Initial & Last Name & Degree

Carlos Castaño Duque, PD Dr

Facility Name

Hospital Clinico Universitario de Valladolid

City

Valladolid

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Juan F. Arenillas, Prof Dr

juanfarenillas@gmail.com

First Name & Middle Initial & Last Name & Degree

Juan F. Arenillas, Prof Dr

First Name & Middle Initial & Last Name & Degree

Mario Martínez-Galdámez, Dr

Facility Name

Kantonsspital Aarau, Department of Interventional and Diagnostical Neuroradiology

City

Aarau

ZIP/Postal Code

5001

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Philipp Gruber, PD Dr.

Phone

+41 62 838 92 94

philipp.gruber@ksa.ch

First Name & Middle Initial & Last Name & Degree

Philipp Gruber, PD Dr.

Facility Name

Department of Interventional and Diagnostical Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel

City

Basel

ZIP/Postal Code

4031

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Marios-Nikos Psychogios, Prof. Dr.

Phone

+41 61 32 86370

marios.psychogios@usb.ch

First Name & Middle Initial & Last Name & Degree

Alex Brehm, Dr.

Phone

+41 61 328 79 48

alex.brehm@usb.ch

First Name & Middle Initial & Last Name & Degree

Marios-Nikos Psychogios, Prof. Dr.

Facility Name

Department of Neurology, University Hospital Basel

City

Basel

ZIP/Postal Code

4031

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Urs Fischer, Prof. Dr.

Phone

+41 31 632 03 64

urs.fischer@usb.ch

First Name & Middle Initial & Last Name & Degree

Urs Fischer, Prof. Dr.

Facility Name

Inselspital Bern, University Clinic for Neuroradiology

City

Bern

ZIP/Postal Code

3010

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jan Gralla, Prof. Dr.

Phone

+41 31 632 26 54

Jan.Gralla@insel.ch

First Name & Middle Initial & Last Name & Degree

Jan Gralla, Prof. Dr.

Facility Name

Geneva University Hospitals, Interventional Neuroradiology Unit

City

Genf

ZIP/Postal Code

1211

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Paolo Machi, Prof. Dr.

Phone

+41 22 372 70 45

Paolo.Machi@hcuge.ch

First Name & Middle Initial & Last Name & Degree

Paolo Machi, Prof. Dr.

Facility Name

Centre hospitalier universitaire vaudois, CHUV

City

Lausanne

ZIP/Postal Code

1011

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Patrik Michel, Prof. Dr.

Phone

+41 21 314 11 90

Patrik.Michel@chuv.ch

First Name & Middle Initial & Last Name & Degree

Patrik Michel, Prof. Dr.

First Name & Middle Initial & Last Name & Degree

Steven Hajdu, Dr.

Facility Name

Neurocentro (EOC) della Svizzera Italiana Stroke Center, Servizio di Neurologia, Ospedale Civico

City

Lugano

ZIP/Postal Code

6900

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Carlo Cereda, PD Dr.

Phone

+41 91 811 66 91

Carlo.Cereda@eoc.ch

First Name & Middle Initial & Last Name & Degree

Carlo Cereda, PD Dr.

First Name & Middle Initial & Last Name & Degree

Allesandro Cianfoni, Prof Dr.

Facility Name

Kantonsspital Luzern

City

Luzern

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Alexander von Hessling, Dr. med

alexander.vonhessling@luks.ch

First Name & Middle Initial & Last Name & Degree

Alexander von Hessling, Dr med

First Name & Middle Initial & Last Name & Degree

Manuel Bolognese, Dr med

Facility Name

Kantonsspital St Gallen

City

Saint Gallen

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Georg Kagi, PD Dr

First Name & Middle Initial & Last Name & Degree

Georg Kagi, PD Dr

First Name & Middle Initial & Last Name & Degree

Claudia Hager, Dr

Facility Name

University Hospital Zurich, Departement of Neuroradiology

City

Zürich

ZIP/Postal Code

8091

Country

Switzerland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Zsolt Kulcsar, PD Dr.

Phone

+41 44 255 56 00

Zsolt.Kulcsar@usz.ch

First Name & Middle Initial & Last Name & Degree

Zsolt Kulcsar, PD Dr.

Facility Name

Barts NHS Health Trust

City

London

Country

United Kingdom

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Paul Bhogal, Dr med

First Name & Middle Initial & Last Name & Degree

Paul Bhogal, Dr med

Facility Name

University Hospitals of North Midlands NHS Trust

City

Stoke-on-Trent

Country

United Kingdom

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Sanjeev Nayak, Dr. med.

Sanjeev.Nayak@uhnm.nhs.uk

First Name & Middle Initial & Last Name & Degree

Sanjeev Nayak, Dr. med.

12. IPD Sharing Statement

Learn more about this trial

EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

We'll reach out to this number within 24 hrs